Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by HUSKISSON, E. C.
Right arrow Articles by JONES, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HUSKISSON, E. C.
Right arrow Articles by JONES, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1982 British Society for Rheumatology

research-article

DICLOFENAC SODIUM, DIFLUNISAL AND NAPROXEN: PATIENT PREFERENCES FOR ANTI-INFLAMMATORY DRUGS IN RHEUMATOID ARTHRITIS

E. C. HUSKISSON, P. A. DIEPPE, J. SCOTT and H. JONES

St. Bartholomew's Hospital London Ec1A 7BE
Bristol Royal Infirmary Bristol BS2 8HW

Correspondence to: Requests for reprints to Dr. E. C. Huskisson, St. Bartholomew's Hospital, London ECIA 7BE.

Ninety patients with active rheumatoid arthritis took part in a cross-over trial comparing diclofenac sodium, diflunisal and naproxen. The efficacy of the three drugs was similar though there were trends in favour of diclofenac sodium in some measurements. The incidence of side-effects was similar with the three drugs and each was chosen by a significant group of patients as continuation therapy at the end of the study.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.